Articles On Imugene (ASX:IMU)

Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of multiple cancers. The company aims to develop novel drugs that work on th...

An Australian-headquartered clinical stage biotechnology company, Imugene Limited (ASX: IMU) seeks to develop different novel immunotherapies to boost the efficacy of cancer treatments. Imugene’s product pipeline covers oncolytic viruses an...

Move over Thomas the Tank Engine – the Oncolytic Express is about to leave the station! The railway analogy is not our own, but the work of Imugene (ASX: IMU) chief Leslie Chong after the company signed a deal to buy an immuno-oncology drug...

An oro-mucosal drug delivery company headquartered in Perth, SUDA Pharmaceuticals Ltd (ASX: SUD) uses its OroMist® technology for the development of low-risk oral sprays. The company reformulates the existing pharmaceuticals into an oral sp...

Queenstown is known as the adventure capital of the world. It attracts over three million people per year to experience the world-class ski runs, zip-line riding, white water rafting, sky diving and is, of course, famous for manufacturing t...

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

An Australian-based biotechnology company, Imugene Limited (ASX: IMU) focuses on the development of cancer immunotherapies targeted at activating the immune system of cancer patients. The company’s exceptional platform technology helps in...

A biotech company headquartered in Australia, Imugene Limited (ASX: IMU) develops new and novel immunotherapies that seek to harness the cancer patients’ immune system against tumors. The company’s unique platform technologies seeks to pote...

Australian immuno-oncology company Imugene (ASX:IMU) has boosted its investigational portfolio through the acquisition of local counterpart Vaxinia with global rights to a new oncolytic virus technology.

A phase-one clinical trial in 30 patients with advanced tumours is expected to start in 2020 across a number of US cancer centres.

A biotechnology company listed on the Australian Stock Exchange (ASX), Imugene Limited (ASX: IMU) develops cancer immunotherapies targeting B-cell peptide vaccines. The immunotherapies developed by the company seek to activate the cancer pa...

Health and medical industry of Australia focuses on the world’s leading technology, advanced research, development and innovation. Over the years, the industry has registered strong growth in terms of both size and reputation. Let us discus...

HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours in gastric, breast, ovarian, lung and pancreatic cancers.

An Australian-headquartered clinical stage immuno-oncology company, Imugene Limited (ASX: IMU) has a robust pipeline of B cell vaccines aimed at treating a variety of cancers. The company’s pipeline includes multiple product candidates that...

The movement of global stock markets is very sensitive to the news which is associated with the trade battle between the US & China, and other macro-economic variables. Not so long ago, it can be said that the global market players were...

Imugene Limited (ASX: IMU) is a clinical-stage immuno-oncology company headquartered in Australia that is engaged in developing a range of immunotherapies used to treat and eradicate tumors. The company’s operations are spread across Americ...

Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.

Imugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field and is developing vaccines to boost and direct the immune system to target and attack cancer cells.